VADS
MIBI-THYR
Value of the Combination Ultrasonography With Ti-RADS Score / Dual Tracer Scintigraphy MIBI-Tc99m/Iodine-123 in the Detection of Malignancy of Thyroid Nodules (Sup or Egal to 15 mm) Classified Bethesda III or IV on Cytology.
Saint-Cloud
VADS
DEBIO 1143-202
Pre-operative window-of-opportunity study of Debio 1143 with or without cisplatin in patients with resectable squamous cell carcinoma of the head and neck.
Paris
CHRISTOPHE LE TOURNEAU
Appareil Digestif
DS8201-A-U207 DESTINY CRC02
A Phase 2, Multicenter, Randomized, Study of Trastuzumab Deruxtecan in Participants With HER2-overexpressing Locally Advanced, Unresectable or Metastatic Colorectal Cancer (DESTINY-CRC02)
Saint-Cloud
VADS
U31287-A-U203 / Patritumab
RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND PHASE 2 STUDY OF PATRITUMAB (U3-1287) IN COMBINATION WITH CETUXIMAB PLUS PLATINUM-BASED THERAPY IN FIRST LINE SETTING IN SUBJECTS WITH RECURRENT OR METASTATIC SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK.
Paris
CHRISTOPHE LE TOURNEAU
Sein métastatique RH+
AIPAC
AIPAC (Active Immunotherapy PAClitaxel): A Multicentre, Phase IIb, Randomised,Double Blind, Placebo-controlled Study in Hormone Receptor-positive Metastatic Breast Carcinoma Patients Receiving IMP321 (LAG-3Ig Fusion Protein) or Placebo as Adjunctive to a Standard Chemotherapy Treatment Regimen of Paclitaxel
Saint-Cloud
ETIENNE BRAIN
Sein métastatique RH+
BYLieve (CBYL719X402)
A Phase II, Multicenter, Open-label, Two-cohort, Non-comparative Study to Assess the Efficacy and Safety of Alpelisib Plus Fulvestrant or Letrozole in Patients With PIK3CA Mutant, Hormone Receptor (HR) Positive, HER2-negative Advanced Breast Cancer (aBC), Who Have Progressed on or After CDK 4/6 Inhibitor Treatment
Saint-Cloud
FLORENCE LEREBOURS
Sein métastatique HER2+
HER2CLIMB (ONT-380-206)
Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib vs Placebo in Combination With Capecitabine and Trastuzumab in Patients With Pretreated Unresectable Locally Advanced or Metastatic HER2+ Breast Carcinoma (HER2CLIMB)
Paris
FRANCESCO RICCI
Sein métastatique RH+
SAFIR PI3K
A Phase II Randomized Trial Comparing Alpelisib and Fulvestrant Versus Chemotherapy as Maintenance Therapy in Patients With PIK3CA Mutated Advanced Breast Cancer
Paris, Saint-Cloud
Sein métastatique RH+
SAFIR-TOR
Identification of the Molecular Alterations Associated With Resistance to Endocrine Therapy and Impacting Treatment With mTOR Inhibitor of HR+ Metastatic Breast Cancer in Post-menopausal Women.
Paris, Saint-Cloud
PAUL-HENRI COTTU
VADS
TOPNIVO - ORL09
A Safety study of Nivolumab in Patients with Recurrent and/or Metastatic Platinum-refractory Squamous Cell Carcinoma of the Head and Neck (SCCHN).
Paris
CHRISTOPHE LE TOURNEAU